BRCA1 and prostate cancer: When contrasting ARID1A LOF mutated patients specifically with BRCA1/2 WT patients within the prostate cancer cohort, a significant depletion of SBS signature 8 mutations remained (Wilcoxon rank-sum test p < 0.0013), which expectedly increased when comparing with BRCA1/2-deficient patients (p < 7.7 × 10−5; Figure 6—figure supplement 2d).